Category: Pharmaceuticals
Global Pharmaceuticals
-
Attapulgite
... 6.9% over the analysis period 2024-2030. Colloidal grade Attapulgite, one of the segments analyzed in the report, is expected to record a 8.5% CAGR and reach US$320.0 Million by the end of the analysis period. ... Read More
-
Fragment-based Drug Discovery
... at a CAGR of 8.8% over the analysis period 2024-2030. Fragment Screening Technology, one of the segments analyzed in the report, is expected to record a 9.9% CAGR and reach US$1.1 Billion by the end ... Read More
-
Transdermal Drug Delivery
... at a CAGR of 16.6% over the analysis period 2024-2030. Passive Delivery System, one of the segments analyzed in the report, is expected to record a 15.1% CAGR and reach US$123.5 Billion by the end ... Read More
-
Triacetin
... 4.3% over the analysis period 2024-2030. Triacetin Plasticizer, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$193.2 Million by the end of the analysis period. Growth ... Read More
-
Gluten Free Products
... at a CAGR of 5.9% over the analysis period 2024-2030. Gluten Free Bakery Products, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$4.7 Billion by the ... Read More
-
Biochemical Reagents
... CAGR of 8.7% over the analysis period 2024-2030. PCR Reagent Kits, one of the segments analyzed in the report, is expected to record a 11.1% CAGR and reach US$6.3 Billion by the end of the ... Read More
-
Biopharmaceutical Fermentation Systems
... at a CAGR of 4.5% over the analysis period 2024-2030. Upstream Products, one of the segments analyzed in the report, is expected to record a 3.7% CAGR and reach US$6.5 Billion by the end of ... Read More
-
Biotechnology
... 8.5% over the analysis period 2024-2030. DNA Sequencing Technology, one of the segments analyzed in the report, is expected to record a 8.6% CAGR and reach US$33.5 Billion by the end of the analysis period. ... Read More
-
Diabetic Shoes
... CAGR of 8.1% over the analysis period 2024-2030. Online Distribution Channel, one of the segments analyzed in the report, is expected to record a 8.5% CAGR and reach US$10.6 Billion by the end of the ... Read More
-
Endometrial Ablation Devices
... at a CAGR of 5.6% over the analysis period 2024-2030. Radiofrequency Ablation, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$628.5 Million by the end of ... Read More
-
Thoracolumbosacral Orthosis (TLSO)
... at a CAGR of 4.7% over the analysis period 2024-2030. The U.S. Market is Estimated at US$584.5 Million While China is Forecast to Grow at 7.2% CAGR The Thoracolumbosacral Orthosis (TLSO) market in the U.S. ... Read More
-
Bone Densitometers
... CAGR of 5.6% over the analysis period 2024-2030. Axial Bone Densitometers, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$264.5 Million by the end of the ... Read More
-
EEG, EMG and Evoked Potential Devices
... reach US$1.7 Billion by 2030, growing at a CAGR of 4.1% over the analysis period 2024-2030. Electroencephalograph Equipment, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach ... Read More
-
Migraine Drugs
... CAGR of 16.0% over the analysis period 2024-2030. Acute Treatment, one of the segments analyzed in the report, is expected to record a 16.6% CAGR and reach US$7.2 Billion by the end of the analysis ... Read More
-
Anti-Infectives
... 6.2% over the analysis period 2024-2030. Anti-Viral Drugs, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$117.1 Billion by the end of the analysis period. Growth ... Read More
-
Ophthalmology Picture Archiving and Communication Systems
... reach US$211.3 Million by 2030, growing at a CAGR of 6.1% over the analysis period 2024-2030. Integrated PACS, one of the segments analyzed in the report, is expected to record a 6.7% CAGR and reach ... Read More
-
e-Prescription Systems
... CAGR of 16.7% over the analysis period 2024-2030. e-Prescription Solutions, one of the segments analyzed in the report, is expected to record a 16.0% CAGR and reach US$3.2 Billion by the end of the analysis ... Read More
-
Bone and Joint Health Supplements
... Billion by 2030, growing at a CAGR of 5.8% over the analysis period 2024-2030. Joint Supplements, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$14.4 Billion ... Read More
-
Parenteral Nutrition
... CAGR of 6.8% over the analysis period 2024-2030. Single Dose Amino Acid Solution, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$4.1 Billion by the end ... Read More
-
Cardiovascular Catheters
... CAGR of 6.6% over the analysis period 2024-2030. Cardiovascular Therapeutic Catheters, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$25.4 Billion by the end of the ... Read More
-
Orthopedic Devices
... CAGR of 6.5% over the analysis period 2024-2030. Joint Reconstruction Devices, one of the segments analyzed in the report, is expected to record a 7.5% CAGR and reach US$44.6 Billion by the end of the ... Read More
-
Peptic Ulcer Testing
... at a CAGR of 5.4% over the analysis period 2024-2030. Laboratory Tests, one of the segments analyzed in the report, is expected to record a 5.9% CAGR and reach US$410.6 Million by the end of ... Read More
-
Breast Biopsy Devices
... at a CAGR of 5.6% over the analysis period 2024-2030. Biopsy Guidance Systems, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$983.4 Million by the end ... Read More
-
Bladder Cancer Therapeutics
... at a CAGR of 4.4% over the analysis period 2024-2030. Transitional Cell Bladder Cancer Therapeutics, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach US$114.6 Million by ... Read More
-
Insulin Delivery Systems
... at a CAGR of 3.2% over the analysis period 2024-2030. Insulin Delivery Syringes, one of the segments analyzed in the report, is expected to record a 3.3% CAGR and reach US$7.0 Billion by the end ... Read More
Research Assistance
